How do I buy Altimmune, Inc. Common Stock (ALT) stock?

Buying Altimmune, Inc. Common Stock (ALT) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "ALT", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ALT by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for ALT on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Altimmune, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Altimmune, Inc. Common Stock (ALT) pay dividends?

At the moment, Altimmune, Inc. Common Stock (ALT) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ALT's performance via the price chart in the Gotrade app.

Is buying ALT on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy ALT?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if ALT is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Altimmune, Inc. Common Stock (ALT) Stock Price: Nov 11 Close $1.93

Latest news

MarketBeat

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

NeutralALTOctober 1, 2026

MarketBeatNeutral

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

ALT

Stocktwits

VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

ALTSeptember 23, 2026

Stocktwits

VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

ALT

Stocktwits

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

ALTSeptember 22, 2026

Stocktwits

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

ALT

Zacks Investment Research

VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t

ALTJuly 30, 2026

Stocktwits

VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t

ALT

Stocktwits

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff

ALTJuly 28, 2026

Stocktwits

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff

ALT

News tone: automated (AI) classification of the article's content, not a price prediction.

About Altimmune, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees57

CEOMr. Jerome Benedict Durso

IPO DateOct 6, 2005

HeadquartersGaithersburg, MD

Key Executives

Name	Title	Year Born
Mr. Jerome Benedict Durso	Chairman, CEO & President	1968
Mr. Gregory L. Weaver CPA, M.B.A.	Chief Financial Officer	1956
Dr. M. Scot Roberts Ph.D.	Chief Scientific Officer	1959
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.	Chief Medical Officer	1963
Mr. Andrew Shutterly M.S.	Principal Financial & Accounting Officer and Corporate Controller	1988
Mr. Bertrand Georges Ph.D.	Chief Technology Officer	—
Mr. Luis Sanay C.F.A.	Vice President of Investor Relations	—
Mr. Tony Blandin B.S.	Vice President of Quality & Compliance Management	—
Ms. Robin E. Abrams J.D.	Chief Legal Officer & Corporate Secretary	1964
Mr. Raymond M. Jordt M.B.A., M.S.	Chief Business Officer	1973

Fundamentals

Valuation

Price-to-sales ratio10,483.33

Price-to-book value0.80

PEG ratio32.62

Profitability

Return on Equity-31.00%

Return on Assets-27.00%

Return on Sales-284594.00%

EBITDA$-88.13M

Trading

Average volume3,508,257

Dividend

Ex dividend date6 Feb 2017

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 32.69
MACD 12/26/9: -0.17
EMA 9 of MACD: -0.19
MACD histogram: 0.02
SMA 50: $2.65; Price below SMA 50
EMA 50: $2.47; Price below EMA 50
SMA 200: $3.16; Price below SMA 200
EMA 200: $3.23; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

1 analyst rating

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $17.00
Average: $17.00
High: $17.00

Evercore ISI Group

Liisa Bayko

Buy

Target price

$17.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-6.0	-7.0
2022	-14.6	-7.1	-16.5	-27.3	+7.2	+137.8	+6.7	+82.5	-41.5	-2.3	-20.5	+52.5
2023	-12.7	-8.6	-65.0	+14.3	-17.9	-14.9	-4.1	-20.2	-1.9	-5.1	+29.0	+215.1
2024	-10.3	+22.5	-15.8	-36.0	+6.2	-11.2	-11.7	+10.0	-3.8	+7.2	+27.2	-18.5
2025	-6.6	+3.3	-16.5	+10.5	+5.0	-27.0	-12.8	+6.1	+0.5	+4.7	+32.8	-26.8
2026	+59.5	-22.3	-26.0	-16.7	+8.2	+1.0	-9.8	+3.7	-7.4	-26.1	-4.5

Compare stocks

ALT

Buy ALT

Market cap

$375.42M

-

Price / Earnings ratio

-4.10

-

Price / Sales ratio

10,483.33

-

Dividend yield

0.00%

-

Average volume

3,508,257

-

Earnings per share

$-0.77

-

Altimmune, Inc. Common Stock (ALT) Stock

Key stats

Compare with ALT

Recent news

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune Q2 Earnings Call Highlights

Altimmune Q2 Earnings Call Highlights

VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t

VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff

About Altimmune, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade